CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. The investigators shall evaluate the graft failure-free, graft-versus-host disease (GVHD)-free survival at one year, frequency of adverse events and post-transplant complications, and immunoreconstitution.

NCT Number	NCT06034535
Lead Sponsor	Hong Kong Children's Hospital
Conditions	Hematopoietic Organs; Disorder
Enrollment	23 participants
Start Date	2023-09-01
Primary Completion	2025-09 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2025-09-15